Glioblastoma Break-in; Try Something New
| Author | Tatyana Alexandrovna Bogoyavlenskaya | en |
| Author | Ekaterina Evgenyevna Tyagunova | en |
| Author | Roman Konstantinovich Kostin | en |
| Author | Alexander Sergeevich Zaharov | en |
| Author | Yuriy Leonidovich Vasil'ev | en |
| Author | Olesya Vasilevna Kytko | en |
| Orcid | Tatyana Alexandrovna Bogoyavlenskaya [0000-0003-3582-8011] | en |
| Orcid | Ekaterina Evgenyevna Tyagunova [0000-0002-5074-6391] | en |
| Orcid | Roman Konstantinovich Kostin [0000-0002-4446-1357] | en |
| Orcid | Alexander Sergeevich Zaharov [0000-0002-4004-7474] | en |
| Orcid | Yuriy Leonidovich Vasil'ev [0000-0003-3541-6068] | en |
| Orcid | Olesya Vasilevna Kytko [0000-0001-5472-415X] | en |
| Issued Date | 2021-01-31 | en |
| Abstract | Context: Glioblastoma is the most invasive brain tumor with a poor prognosis and rapid progression. The standard therapy (surgical resection, adjuvant chemotherapy, and radiotherapy) ensures survival only up to 18 months. In this article, we focus on innovative types of radiotherapy, various combinations of temozolomide with novel substances, and methods of their administration and vector delivery to tumor cells. Evidence Acquisition: For a detailed study of the various options for chemotherapy and radiotherapy, Elsevier, NCBI MedLine, Scopus, Google Scholar, Embase, Web of Science, The Cochrane Library, EMBASE, Global Health, CyberLeninka, and RSCI databases were analyzed. Results: The most available method is oral or intravenous administration of temozolomide. More efficient is the combined chemotherapy of temozolomide with innovative drugs and substances such as lomustine, histone deacetylase inhibitors, and chloroquine, as well as olaparib. These combinations improve patient survival and are effective in the treatment of resistant tumors. Compared to standard fractionated radiotherapy (60 Gy, 30 fractions, 6 weeks), hypofractionated is more effective for elderly patients due to lack of toxicity; brachytherapy reduces the risk of glioblastoma recurrence, while radiosurgery with bevacizumab is more effective against recurrent or inoperable tumors. Currently, the most effective treatment is considered to be the intranasal administration of anti-Ephrin A3 (anti-EPHA3)-modified containing temozolomide butyl ester-loaded (TBE-loaded) poly lactide-co-glycolide nanoparticles (P-NPs) coated with N-trimethylated chitosan (TMC) to overcome nasociliary clearance. Conclusions: New radiotherapeutic methods significantly increase the survival rates of glioblastoma patients. With some improvement, it may lead to the elimination of all tumor cells leaving the healthy alive. New chemotherapeutic drugs show impressive results with adjuvant temozolomide. Anti-EPHA3-modified TBE-loaded P-NPs coated with TMC have high absorption specificity and kill glioblastoma cells effectively. A new “step forward” may become a medicine of the future, which reduces the specific accumulation of nanoparticles in the lungs, but simultaneously does not affect specific absorption by tumor cells. | en |
| DOI | https://doi.org/10.5812/ijcm.109054 | en |
| Keyword | EPHA3 Antibody | en |
| Keyword | Glioblastoma Multiforme (GBM) | en |
| Keyword | Nose-to-brain Delivery | en |
| Keyword | Temozolomide | en |
| Keyword | Brachytherapy | en |
| Keyword | Gamma Knife Radiosurgery | en |
| Keyword | External-beam Radiotherapy | en |
| Keyword | Lomustine | en |
| Keyword | Suberoylanilide hydroxamic acid (SAHA) | en |
| Keyword | Olaparib | en |
| Publisher | Brieflands | en |
| Title | Glioblastoma Break-in; Try Something New | en |
| Type | Review Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijcm-14-1-109054.pdf
- Size:
- 256.93 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF